EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Mar. 1, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, announced today that its proprietary hydrophilic technology is being used on Medtronic’s U.S. Food and Drug Administration (FDA) approved Resolute Integrity™ Drug-Eluting Stent (DES) delivery system for the treatment of coronary artery disease (CAD).

“We are extremely pleased that our hydrophilic coating was selected for use on the delivery catheter of Medtronic’s Resolute Integrity DES delivery system. SurModics values the long-standing relationship with Medtronic and remains steadfast in complementing the deliverability of the Resolute Integrity DES through our advanced hydrophilic coating platforms” said Gary Maharaj, President and CEO of SurModics.

Advanced deliverability to successfully navigate the challenging anatomical sites faced by today’s interventional cardiologist is one unique attribute of the Resolute Integrity DES system.

About SurModics, Inc.
SurModics’ mission is to exceed our customer's expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world’s leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit http://www.surmodics.com. The content of SurModics’ website is not part of this release or part of any filings the Company makes with the SEC.

Source: SurModics, Inc.

SurModics, Inc.
Timothy J. Arens, 952-500-7000
Vice President of Finance and interim Chief Financial Officer